A matched case-control study of Triple negative vs. HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high risk features and poor outcome.
Gulf J Oncolog
; (7): 14-20, 2010 Jan.
Article
em En
| MEDLINE
| ID: mdl-20164004
ABSTRACT
Genetic profile studies of breast cancer identified a number of biologically different subtypes. These genetic subtypes are often surrogated by estrogen receptors (ER), progesterone receptors (PR) and HER2 status as measured by immunohistochemistry (IHC). Triple negative (TN) subtype is recognized to have high risk features and poor outcome. Over expression of the HER2 is also recognized as a poor outcome marker. The characteristics and outcome of HER2 positive tumours (irrespective of hormonal status) (HER2 HR+/-) identified by IHC have not addressed in the era of surrogate genetic subtyping. Therefore, we retrospectively compared the risk features and clinical outcome of patients with TN against these with HER2 HR+/- tumours.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Receptores de Progesterona
/
Receptores de Estrogênio
/
Biomarcadores Tumorais
/
Receptor ErbB-2
/
Neoplasias Hormônio-Dependentes
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Gulf J Oncolog
Ano de publicação:
2010
Tipo de documento:
Article